JD
Joshua R. Disbrow
Chief Executive OfficerDirector

Joshua R. Disbrow insider trades: Aytu Biopharma (AYTU) stock purchases

Chief Executive Officer, Aytu Biopharma Last trade Jun 9, 2025 35 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
10
Open-market trades
since 2016
3
Companies
last trade 2025

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Joshua reports to the SEC

Open-market buys and sales

10 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jun 9, 2025AYTU↑ Buy$100K
Feb 28, 2025AYTU↑ Buy$20K
Jul 29, 2024ZYXI↑ Buy$58K
Jun 14, 2023AYTU↑ Buy$26K
Dec 19, 2022AYTU↑ Buy$25K
Dec 19, 2019AYTU↑ Buy$49K
Mar 6, 2018AYTU↑ Buy$102K
Nov 2, 2016AYTU↑ Buy$250K
May 6, 2016AYTU↑ Buy$100K
Jan 20, 2016AYTU↑ Buy$100K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Joshua R. Disbrow's insider trades

Joshua R. Disbrow is Chief Executive Officer at Aytu Biopharma (AYTU). Since Jan 20, 2016, Joshua has reported 10 open-market purchases worth $829K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (21 filings), shares returned to the company (4 filings), other transactions (4 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AYTU insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.